<DOC>
	<DOCNO>NCT01219855</DOCNO>
	<brief_summary>This study investigate level repeat dose CTAP101 change body time ( pharmacokinetics , PK ) CTAP101 affect mineral hormonal balance ( pharmacodynamics , PD ) patient chronic kidney disease ( CKD , vitamin D insufficiency secondary hyperparathyroidism ( SHPT ) .</brief_summary>
	<brief_title>Safety/Efficacy Study CTAP101 Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism ( SHPT )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<criteria>1 . Urinary albumin excretion ≤3000 μg creatinine 2 . Stage 3 CKD 3 . Plasma iPTH : &gt; 70 pg/mL &lt; 500 pg/mL 4 . Serum Ca : ≥ 8.4 mg/dL &lt; 10.0 mg/dL 5 . Serum P : ≥ 2.0 mg/dL &lt; 5.0 mg/dL 6 . Serum 25hydroxyvitamin D : &gt; 10 ng/mL &lt; 29 ng/mL . 7 . Discontinue vitamin D use duration study 1 . History kidney transplant parathyroidectomy 2 . Spot urine calcium : creatinine ratio &gt; 0.2 3 . Current serious illness , malignancy , HIV , liver disease , cardiovascular event hepatitis 4 . Currently dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Parathyroid Diseases</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Kidney Failure , Chronic</keyword>
	<keyword>Hyperparathyroidism , Secondary</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Hyperparathyroidism</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Kidney Failure</keyword>
	<keyword>Renal Insufficiency , Chronic</keyword>
</DOC>